Global Male Infertility Market to Reach $6.5 Billion by 2030
The global market for Male Infertility estimated at US$3.4 Billion in the year 2022, is projected to reach a revised size of US$6.5 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2022-2030. DNA Fragmentation Technique, one of the segments analyzed in the report, is projected to record 8.1% CAGR and reach US$1.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Oxidative Stress Analysis segment is readjusted to a revised 8.1% CAGR for the next 8-year period.The U.S. Market is Estimated at $916 Million, While China is Forecast to Grow at 12.6% CAGR
The Male Infertility market in the U.S. is estimated at US$916 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 7.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.7% CAGR.Select Competitors (Total 32 Featured) -
- Andrology Solutions
- Bayer AG
- Cadila Pharmaceuticals Ltd.
- Endo Pharmaceuticals Inc.
- Halotech DNA
- Intas Pharmaceuticals Ltd.
- Merck KGaA
- Sanofi
- SCSA Diagnostics, Inc.
- Vitrolife
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Andrology Solutions
- Bayer AG
- Cadila Pharmaceuticals Ltd.
- Endo Pharmaceuticals Inc.
- Halotech DNA
- Intas Pharmaceuticals Ltd.
- Merck KGaA
- Sanofi
- SCSA Diagnostics, Inc.
- Vitrolife
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 88 |
Published | March 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 3.4 Billion |
Forecasted Market Value ( USD | $ 6.5 Billion |
Compound Annual Growth Rate | 8.4% |
Regions Covered | Global |